Stacey Pugh is the founder of Endogenex. Endogenex has raised $138M in total funding. Latest round: Series C. Based in Minneapolis, United States.
Stacey Pugh is the CEO of Endogenex, a clinical-stage medical technology company developing a new treatment for type 2 diabetes. The company focuses on a minimally invasive endoscopic procedure to treat inflamed tissue in the duodenum, aiming to restore healthy cell regeneration. Endogenex recently closed a $50 million Series C extension, bringing their total Series C financing to $138 million, to fund their pivotal ReCET Clinical Study and pursue FDA approval.
Full founder directory · Investor directory · Company funding database · Fundraising library